National Cancer Institute Cancer Currents Blog: Can Targeted Therapy for KRAS Mutations Double as Part of Immunotherapy?
Some of the deadliest cancers have mutations in a gene called KRAS. The recent development of drugs that can kill cancer cells with these mutations has been heralded as a major breakthrough. But in nearly all patients, tumors eventually become resistant to these drugs, and they stop working.
Two research teams have now developed a way to overcome this resistance that may enable KRAS-targeted drugs—and perhaps drugs that target other mutant cancer-causing proteins in cancer cells—to pull double duty as an immunotherapy.